(Q57191836)

7

0 references

Hermann Brenner

H. Brenner

Hermann Brenner

14

0 references

Ben Schöttker

Ben Schöttker

B. Schottker

2

0 references

Marcus E Kleber

Marcus E Kleber

M. E. Kleber

5

0 references

Ulf Landmesser

16

Ulf Landmesser

U. Landmesser

0 references

Winfried März

17

Winfried März

W. Marz

0 references

Hubert Scharnagl

4

Hubert Scharnagl

H. Scharnagl

0 references

Tanja B Grammer

6

Tanja B Grammer

T. B. Grammer

0 references

Stefan Blankenberg

15

Stefan Blankenberg

S. Blankenberg

0 references

Renate B. Schnabel

13

Renate B Schnabel

R. B. Schnabel

0 references

Sebastian Appelbaum

3

Sebastian Appelbaum

0 references

author name string

Guenther Silbernagel

1

0 references

Ute Mons

8

0 references

Bernd Holleczek

9

0 references

Georg Goliasch

10

0 references

Alexander Niessner

11

0 references

Bernhard O Boehm

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

12

0 references

language of work or name

English

0 references

publication date

7 September 2013

0 references

December 2013

0 references

published in

European Heart Journal

0 references

volume

34

0 references

issue

46

0 references

page(s)

3563-3571

0 references

3563-71

0 references

cites work

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Major lipids, apolipoproteins, and risk of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

High-density lipoprotein and coronary heart disease: current and future therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Evidence of a synergistic association between heart rate, inflammation, and cardiovascular mortality in patients undergoing coronary angiography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients with Coronary Artery Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Changes of cardiovascular risk factors and their implications in subsequent birth cohorts of older adults in Germany: a life course approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Proinflammatory cytokines, adiponectin, and increased risk of primary cardiovascular events in diabetic patients with or without renal dysfunction: results from the ESTHER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Biological activities of HDL subpopulations and their relevance to cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343

Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHT343